Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent Biologics's ROE % for the quarter that ended in Dec. 2025 was -0.25%. Innovent Biologics's PB Ratio for the quarter that ended in Dec. 2025 was 6.21.
Innovent Biologics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -0.04%.
Innovent Biologics ROE % Adjusted to Book Value Related Terms
Innovent Biologics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics ROE % Adjusted to Book Value Chart
STU:6IB vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Innovent Biologics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -0.04% mean?
Innovent Biologics (STU:6IB) has a ROE % Adjusted to Book Value of -0.04% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' ROE % Adjusted to Book Value too high?
Innovent Biologics' current ROE % Adjusted to Book Value is -0.04%. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Innovent Biologics' ROE % Adjusted to Book Value of -0.04% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current ROE % Adjusted to Book Value is -0.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.20, compared to a current price of €10.10 — trading 9.8% below its estimated fair value. The current ROE % Adjusted to Book Value is -0.04%. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current ROE % Adjusted to Book Value is -0.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €10.10 is trading 9.8% below its estimated GF Value™ of €11.20.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
ROE % Adjusted to Book Value: -0.04%
GF Value™: €11.20 vs. price of €10.10 (9.8% below fair value)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
